论文部分内容阅读
目的观察氨溴索联合布地奈德雾化吸入对慢性阻塞性疾病急性加重期(AECOPD)的临床疗效。方法将70例AECOPD患者随机分为两组,治疗组和对照组各35例。治疗组在常规治疗的基础上加氨溴索粉针30mg及布地奈德混悬液2mg,生理盐水稀释氧气驱动雾化吸入,每天2次;对照组在常规治疗的基础上加糜蛋白酶粉针4000单位及布地奈德混悬液2mg,生理盐水稀释氧气驱动雾化吸入,每天2次;治疗结束后分别对患者的部分临床症状、体征,实验室检查,肺功能及不良反应进行比较。结果治疗前两组各项观察指标无差异(P>0.05),治疗后治疗组在临床症状、体征,实验室检查及肺功能检测方面与对照组比较有显著好转,不良发生率低,差异且有统计学意义(P<0.05)。结论 AECOPD患者应用氨溴索联合布地奈德雾化吸入治疗,可明显提高疗效,值得临床推广。
Objective To observe the clinical efficacy of ambroxol combined with budesonide inhalation on acute exacerbation of chronic obstructive disease (AECOPD). Methods AECOPD 70 patients were randomly divided into two groups, the treatment group and the control group of 35 cases. Treatment group on the basis of conventional treatment plus ambroxol 30mg and budesonide suspension 2mg, diluted with saline to drive aerosol inhalation, 2 times a day; the control group on the basis of conventional treatment with chymotrypsin powder 4000 units and budesonide suspension 2mg, saline diluted aerosol inhalation inhalation, 2 times a day; after treatment were part of the clinical symptoms, signs, laboratory tests, lung function and adverse reactions were compared. Results There was no significant difference between the two groups before treatment (P> 0.05). After treatment, the treatment group showed significant improvement in clinical symptoms, signs, laboratory tests and pulmonary function tests compared with the control group, with a low incidence of adverse reactions There was statistical significance (P <0.05). Conclusions AECOPD patients treated with ambroxol combined with budesonide inhalation can significantly improve the curative effect and deserve clinical promotion.